This biotech company’s drug for treating hypoactive sexual desire disorder in women is expected to receive FDA approval in early January 2019. With increasing market demand for HSDD treatments, and the fact that its drug is more effective than the competition, now could be a good time to invest in its stock. CLICK HERE.
